

Amendments to the Specification:

Please replace the paragraph appearing on page 5, lines 13-18 with the following amended paragraph:

A 63 year old woman with advanced carcinoid metastatic to the liver and mesentery had had prior treatment with 5-fluorouracil with disease progression noted in 2001 in spite of etoposide therapy. In month 1, she was having increasing symptoms of carcinoid syndrome consisting of significant fatigue, diarrhea, and tearing in spite of increasing doses of octreotide (SandostatinTM) SANDOSTATIN LAR® (octreotide acetate for injectable suspension; 20 mg) administered subcutaneously on a monthly basis.